Skip to main navigation Skip to search Skip to main content

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Translated title of the contribution: Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
  • Trial Investigators DREAM
  • , G.R. Dagenais
  • , H.P.F. Koppeschaar
  • , J. Poque
  • , S. Yusuf

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionEffects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Original languageUndefined/Unknown
Pages (from-to)1007-1014
Number of pages8
JournalDiabetes Care
Volume31
Issue number5
Publication statusPublished - 2008

Cite this